Migraine is one of the most frequent disabling diseases today, and its prevention is one of the greatest challenges for our society. For this Ajovy was produced, a new drug that can help fight this evil.
Migraine is not just a headache: it is a neurological disease that appears suddenly and is suffered by more than 50 million patients in Europe. It is a physically and psychologically debilitating disorder. It usually occurs between the ages of 25 and 55 and has a great impact on the person’s life. It is more common in women and has a certain genetic component.
Migraine is recognized as a disabling disease. Although more and more work is being done to improve its prophylaxis in order to be able to control it and reduce its impact, there are many cases in which it is not possible to diagnose it or to establish an adequate method of intervention.
New therapeutic alternatives, such as the Ajovy drug , are key to advancing the treatment of this disease. Both migraine prevention and symptomatic treatments are important to reduce its impact.
This new drug was studied in patients with disabling migraine. Ajovy has been shown to be useful in reducing up to 50% of migraine days in a month. Several studies ensure its effectiveness as a preventive method.
Another drug that has been used to date for migraine prophylaxis is propranolol. This medicine, marketed as Inderal, is a relaxing drug also used for anxiety.
Features of Ajovy and how does it work?
Ajovy is the brand name for the fremanezumab monoclonal antibody. It is an injectable solution indicated for the prevention of migraine in adults suffering from this disorder at least four days a month. As for recognition and use, it has been approved in both the United States and Europe.
Fremanezumab is a humanized monoclonal antibody. It works by attaching itself to the peptide related to the calcitonin gene (CGRP), and prevents it from binding to its receptor. This is why it is called an anti-CGRP. The CGRP is one of the most abundant neuropeptides that are produced both in the central neurons in the periphery. It is a powerful vasodilator and affects pain transmission.
CGRP levels have been shown to rise during migraines. When this neuropeptide is released in the nerve endings and joins its receptor, it causes a secretion of inflammatory mediators, also causing strong vasodilation.
By acting on the CGPR, therefore, fremanezumab avoids the activation of sensory fibers of the trigeminal nerve, responsible for the activation of pain. However, the mechanisms that cause these substances to act are not yet fully known.
Administration to prevent migraines
Ajovy comes with an easy-to-use preloaded pipette to inject the drug under the skin. Each preloaded injection contains 225 milligrams of antibodies and can be administered on a monthly or quarterly basis.
- If administered monthly, a subcutaneous injection is sufficient.
- When given quarterly, three syringes are injected at a time, or 675 milligrams. The dose, as we see, remains unchanged.
This method of administration implies a great advantage as it increases the flexibility of the treatment. If you opt for the quarterly option, four administrations per year are enough to cover the time frame envisaged by the treatment.
Ajovy side effects
The adverse reactions observed were generally mild in nature. Reactions on the skin around the injection site have been identified, such as:
As this is a new drug, however, it is necessary to continue to study its safety and efficacy over the long term. If unwanted reactions are noted, a specialist should be consulted immediately.
Not all treatments work for all patients for migraines . This is because there are different types of migraines. The specialist doctor will therefore indicate which drug is best suited to your specific case, thus personalizing the treatment.